Life With GLP-1s
Clinical and cultural conversations around obesity have long revolved around BMI (and its credibility), harmful stereotypes, issues of equity and the multi-million dollar weight loss industry.
Read Resource
Glucagon-like peptide 1 (GLP-1) agonists are a class of medications that improves blood sugar control and drives weight loss. Omada is helping customers and prospects navigate this new space by ensuring members who choose to get a prescription are taking it in conjunction with our behavior change prevention and diabetes programs, as outlined by the FDA.
Clinical and cultural conversations around obesity have long revolved around BMI (and its credibility), harmful stereotypes, issues of equity and the multi-million dollar weight loss industry.
Read Resource
A side-effect of taking GLP-1s is a loss of muscle mass. Julie Mulcahy, PT, DPT, CAPP OB explores how to combat this with resistance exercises.
Read Article
Findings show that meaningfully engaged Omada members on GLP-1s achieved an average of 1.7 times greater weight loss, and inform a new collaboration with Evernorth's EncircleRx program.
Read Article
Error - something went wrong!
Subscribe to the Omada Insider monthly newsletter for thought leadership, industry insights and the newest happenings
Thank you!
Omada delivers GLP-1 FAQs focusing on weight loss quantity vs. quality with timely data and insights for employers, health plans and benefit consultants.
Read Article
Omada Health Enhances GLP-1 Care Track to Support Customers Managing Medications and Integrates MSK Support.
Read Article
Obesity is one of the clearest case studies of health disparities that exist in the U.S., having the biggest impact on Black and Hispanic adults, low-income populations, and people covered by Medicaid
Read Article
Analysis shows GLP-1s are twice as effective with lifestyle support programs. Download this free report by Omada Health and Express Scripts to learn more.
Read Resource
Weight is hard to lose, but harder to keep off. Even GLP-1 users won’t stay on them forever. What’s life like after GLP-1s? Tune into our webinar and find out.
Watch Video
GLP-1 agonist medications have had impressive initial outcomes. However, the long-term effects on a patient’s health beyond the trial timelines and on the costs to the healthcare system are uncertain.
Read Article
Following up on our first GLP-1s webinar this one will address employers' most pressing questions around the risks and side effects of GLP-1s.
Watch Video
The price of GLP-1 medication is a concern for stakeholders throughout the healthcare industry. Omada breaks down the list of GLP-1s by FDA approval stage, & what more GLP-1s could mean for costs.
Read Article
GLP-1s are effective options for weight management, but costs and side effects matter. Dive into the history and overview of GLP-1s in our 2-minute video.
Watch Video
GLP-1s like Ozempic and Wegovy can be costly. Learn how high prices of GLP-1s can potentially impact the healthcare ecosystem in our 2-minute video.
Watch Video
GLP-1s like Ozempic are prescribed alongside lifestyle changes like diet and exercise. Watch this video to learn about their effectiveness and side effects.
Watch Video
Should patients be on GLP-1 medications long term? Watch this 2-minute video to learn what type of patients should be taking GLP-1s for weight loss.
Watch Video
In the fifth installment of Omada’s video blog series, we cover how we approach access to GLP-1 medications.
Watch Video
In the sixth installment of Omada’s video blog series, we cover why we are not prescribing GLP-1s to members.
Watch Video
In the last installment of our video series, we overview how support members with a unique layer of support for those who have chosen any “next level” obesity care.
Watch Video
GLP-1s have taken the healthcare industry – and pop culture – by storm as an effective class of medication to help treat chronic obesity. The exploding popularity of GLP-1s for weight loss has created
Watch Video
You’ve asked, and we’ve answered - your top questions about how Omada can help with your strategy for addressing GLP-1s. By Wei-Li Shao, President, Omada Health
Read Article
Loading More...